[go: up one dir, main page]

PA8849001A1 - Anticuerpos de c-met - Google Patents

Anticuerpos de c-met

Info

Publication number
PA8849001A1
PA8849001A1 PA20098849001A PA8849001A PA8849001A1 PA 8849001 A1 PA8849001 A1 PA 8849001A1 PA 20098849001 A PA20098849001 A PA 20098849001A PA 8849001 A PA8849001 A PA 8849001A PA 8849001 A1 PA8849001 A1 PA 8849001A1
Authority
PA
Panama
Prior art keywords
met antibodies
met
disorders
pathogenesis
union
Prior art date
Application number
PA20098849001A
Other languages
English (en)
Inventor
Davies Julian
Liu Ling
Lu Jirong
Edward Vaillancourt Peter
Andrew Wortinger Mark
Zeng Wei
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PA8849001A1 publication Critical patent/PA8849001A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE PROVEEN ANTICUERPOS MONOCLONALES, FRAGMENTOS DE UNIÓN A ANTÍGENO DE LOS MISMOS, Y COMBINACIONES DE OS ANTERIORES, QUE SE UNEN, E INHIBEN LA ACTIVIDAD DE C-MET, Y QUE SON EFECTIVOS EN EL TRATAMIENTO DE CÁNCERES Y OTRAS ENFERMEDADES, TRASTORNOS O CONDICIONES DONDE LA PATOGÉNESIS ESTÁ MEDIADA POR C-MET.
PA20098849001A 2008-11-21 2009-11-13 Anticuerpos de c-met PA8849001A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11682508P 2008-11-21 2008-11-21
US21990309P 2009-06-24 2009-06-24

Publications (1)

Publication Number Publication Date
PA8849001A1 true PA8849001A1 (es) 2010-06-28

Family

ID=41435259

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098849001A PA8849001A1 (es) 2008-11-21 2009-11-13 Anticuerpos de c-met

Country Status (27)

Country Link
US (2) US8217148B2 (es)
EP (2) EP2963058B1 (es)
JP (1) JP5688027B2 (es)
KR (1) KR101334450B1 (es)
CN (1) CN102216333B (es)
AR (1) AR074360A1 (es)
AU (1) AU2009316742B2 (es)
BR (1) BRPI0922800A2 (es)
CA (1) CA2743508C (es)
CY (1) CY1116886T1 (es)
DK (1) DK2358755T3 (es)
EA (1) EA020398B1 (es)
ES (2) ES2663825T3 (es)
HR (1) HRP20151019T1 (es)
HU (1) HUE026058T2 (es)
IL (1) IL212633A (es)
JO (1) JO3097B1 (es)
MX (1) MX2011005400A (es)
NZ (1) NZ592215A (es)
PA (1) PA8849001A1 (es)
PL (1) PL2358755T3 (es)
PT (1) PT2358755E (es)
SI (1) SI2358755T1 (es)
TR (1) TR201802841T4 (es)
TW (1) TWI477284B (es)
WO (1) WO2010059654A1 (es)
ZA (1) ZA201103586B (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
EP2545077B1 (en) 2010-03-10 2018-10-31 Genmab A/S Monoclonal antibodies against c-met
WO2011150454A1 (en) * 2010-06-01 2011-12-08 Monash University ANTIBODIES DIRECTED TO THE UNPROCESSED RECEPTOR TYROSINE KINASE c-MET
RU2013114360A (ru) 2010-08-31 2014-10-10 Дженентек, Инк. Биомаркеры и способы лечения
CA2809677A1 (en) 2010-09-03 2012-03-08 Academia Sinica Anti-c-met antibody and methods of use thereof
CN103562223B (zh) 2010-11-03 2017-02-22 阿尔金-X有限公司 抗c‑Met抗体
CN102276726B (zh) * 2011-03-16 2014-02-19 常州新泉生物医药科技有限公司 肝细胞生长因子受体活性基团的融合蛋白
WO2012174529A2 (en) * 2011-06-17 2012-12-20 Indiana University Research And Technology Corporation Methods for increasing the potency and efficacy of stem cells
CA2846630A1 (en) 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
US9201074B2 (en) 2011-09-20 2015-12-01 Eli Lilly And Company Anti-c-Met antibodies
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
KR20130037153A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 및 그의 용도
KR101865223B1 (ko) * 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
SG11201402485UA (en) 2011-11-21 2014-06-27 Genentech Inc Purification of anti-c-met antibodies
US20150147274A1 (en) 2011-12-02 2015-05-28 Cancer Research Technology Limited Antibodies against hgf - receptor and uses
US9260531B2 (en) * 2012-05-09 2016-02-16 Eli Lilly And Company Anti-c-met antibodies
CN109503714A (zh) * 2012-06-21 2019-03-22 索伦托治疗有限公司 与c-Met结合的抗原结合蛋白
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
SI2766048T1 (sl) 2012-10-12 2015-03-31 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
EP2958592A1 (en) 2013-02-22 2015-12-30 F. Hoffmann-La Roche AG Methods of treating cancer and preventing drug resistance
CN105209077B (zh) 2013-03-13 2019-06-11 麦迪穆有限责任公司 吡咯并苯并二氮杂卓以及其结合物
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
KR102042174B1 (ko) * 2013-03-29 2019-11-08 삼성전자주식회사 인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도
WO2014178791A1 (en) * 2013-04-30 2014-11-06 Agency For Science, Technology And Research Mab 2 anti-met antibody
US20160130660A1 (en) * 2013-08-14 2016-05-12 Qiagen Mansfield, Inc. Compositions and methods for multimodal analysis of cmet nucleic acids
CA2926262C (en) * 2013-10-14 2025-06-17 Janssen Biotech Inc CYSTEINE MODIFIED TYPE III FIBRONECTIN DOMAIN BINDING MOLECULES (FN3)
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
TW201609805A (zh) * 2013-12-23 2016-03-16 美國禮來大藥廠 結合ｅｇｆｒ及ｍｅｔ之多功能抗體
TW201622744A (zh) * 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
CN107002119A (zh) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
KR20170005016A (ko) 2014-05-23 2017-01-11 제넨테크, 인크. MiT 바이오마커 및 그의 사용 방법
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CA2961323C (en) * 2014-09-16 2021-11-30 Symphogen A/S Anti-met antibodies and compositions
WO2016091891A1 (en) 2014-12-09 2016-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against axl
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US20180057595A1 (en) 2015-03-16 2018-03-01 Celldex Therapeutics, Inc. Anti-MET Antibodies and Methods of Use Thereof
WO2017019454A2 (en) * 2015-07-28 2017-02-02 Musc Foundation For Research Development Identification of novel anti-fibrotic peptide in c-terminal region of the met receptor tyrosine kinase
EP3909984A1 (en) 2015-11-03 2021-11-17 Merck Patent GmbH Affinity matured c-met antibodies
CN106810611A (zh) * 2015-11-30 2017-06-09 中国科学院深圳先进技术研究院 抗cMet和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
KR102476846B1 (ko) 2016-02-05 2022-12-12 주식회사 헬릭스미스 항―ｃ―ＭＥＴ 항체 및 이의 용도
GB2551372A (en) * 2016-06-16 2017-12-20 Bombardier Primove Gmbh A secondary unit, a system for inductive power transfer and a method for operating a secondary unit and a system for inductive power transfer
EP3471750A4 (en) 2016-06-21 2020-02-26 Janssen Biotech, Inc. Cysteine engineered fibronectin type iii domain binding molecules
CN107573416A (zh) * 2016-06-30 2018-01-12 中国科学院深圳先进技术研究院 抗igf1r和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
CN107556387A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗gpc3和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
CN107556388A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用
CN107556386A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗EGFRvIII和CD3特异性双靶向抗体、含双靶向抗体表达盒的微环DNA及应用
EP3492105A4 (en) * 2016-07-26 2020-02-26 Nihon University THERAPEUTIC AGENT FOR PERIODONTITIS.
US10439449B2 (en) * 2016-08-10 2019-10-08 Microsoft Technology Licensing, Llc Coupling device modules for inductive data transmission
CN116903742A (zh) * 2016-09-29 2023-10-20 田边三菱制药株式会社 cMET单克隆结合剂、其药物缀合物及其用途
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
IL265800B2 (en) 2016-10-11 2023-10-01 Agenus Inc Anti-LAG-3 antibodies and methods of using them
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
ES2866348T3 (es) 2016-11-16 2021-10-19 Lilly Co Eli Terapia de combinación para el cáncer con mutación o mutaciones de omisión del exón 14 o fenotipo de omisión del exón 14
PT3544634T (pt) * 2016-11-23 2021-06-02 Lilly Co Eli Conjugados anticorpo-fármaco anti-met
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
US10626165B2 (en) 2016-12-14 2020-04-21 Janssen Biotech, Inc. CD8a-binding fibronectin type III domains
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
US20180230218A1 (en) * 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN106986932A (zh) * 2017-04-06 2017-07-28 海口市人民医院 一种c‑Met表位肽及其应用
RU2751720C2 (ru) * 2017-05-30 2021-07-16 Чонг Кун Данг Фармасьютикал Корп. Новое анти-с-мет антитело и его применение
CN109771642B (zh) 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
GB201803892D0 (en) * 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
US20220111065A1 (en) 2018-05-23 2022-04-14 Adc Therapeutics Sa Molecular adjuvant
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
EP4045061A4 (en) 2019-10-14 2024-04-17 ARO Biotherapeutics Company FIBRONECTIN TYPE III DOMAINS BINDING TO CD137
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
MX2023009146A (es) * 2021-02-03 2023-08-17 Mythic Therapeutics Inc Anticuerpos y usos de estos.
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4320152A1 (en) 2021-04-08 2024-02-14 Byondis B.V. Anti-c-met antibodies and antibody-drug conjugates
AU2022258584A1 (en) 2021-04-14 2023-10-12 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
EP4323409A4 (en) 2021-04-14 2025-04-16 ARO Biotherapeutics Company CD71-BINDING FIBRONECTIN TYPE III DOMAINS
CN113788895B (zh) * 2021-10-14 2023-09-15 陕西健吉跃生物科技有限公司 一种兔多克隆抗体及其制备方法和应用
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
AU2024277829A1 (en) 2023-05-19 2025-12-04 Les Laboratoires Servier Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof
WO2025025434A1 (zh) * 2023-08-02 2025-02-06 百泰生物药业有限公司 EGFR/c-Met双特异性抗体及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2104914T3 (es) 1991-05-10 1997-10-16 Pharmacia & Upjohn Spa Formas truncadas del factor de crecimiento de hepatocitos (hgf).
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US6416758B1 (en) 1999-04-28 2002-07-09 Board Of Regents, The University Of Texax System Antibody conjugate kits for selectively inhibiting VEGF
BRPI0407446A (pt) 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
ITMI20031127A1 (it) 2003-06-05 2004-12-06 Uni Degli Studi Del Piemont E Orientale Am Anticorpi anti-hgf-r e loro uso
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
KR100556660B1 (ko) * 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
US20050233960A1 (en) 2003-12-11 2005-10-20 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
WO2005063816A2 (en) 2003-12-19 2005-07-14 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
BRPI0513666A (pt) * 2004-08-05 2008-05-13 Genentech Inc anticorpos, anticorpos anti c-met humanizados, método de inibição de proliferação celular de c-met ativado, método de modulação de uma doença associada com descontrole de sinalização de hgf/c-met, método para o tratamento de um sujeito com cáncer, método para o tratamento de um distúrbio proliferativo, ácido nucléico, célula hospedeira e composição
MX2007011652A (es) 2005-03-25 2007-11-14 Genentech Inc Metodos y composiciones para modular c-met hiperestabilizado.
CA2638889C (en) 2006-02-06 2015-06-02 Metheresis Translational Research S.A. Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
CA2638869A1 (en) * 2006-02-22 2007-09-07 Eli Lilly And Company Humanized anti-ghrelin antibodies
ES2386738T3 (es) 2006-03-30 2012-08-28 Novartis Ag Composiciones y métodos de uso para anticuerpos de C-MET
KR100829972B1 (ko) 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
ES2392637T3 (es) * 2007-02-08 2012-12-12 The Regents Of The University Of California Mutaciones de Gnaq en el melanoma
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met

Also Published As

Publication number Publication date
TR201802841T4 (tr) 2018-03-21
HUE026058T2 (en) 2016-05-30
AU2009316742B2 (en) 2012-06-07
AR074360A1 (es) 2011-01-12
EP2963058A1 (en) 2016-01-06
EA201170716A1 (ru) 2011-12-30
MX2011005400A (es) 2011-06-20
IL212633A (en) 2015-03-31
JP5688027B2 (ja) 2015-03-25
SI2358755T1 (sl) 2015-10-30
US8398974B2 (en) 2013-03-19
ZA201103586B (en) 2013-10-30
EA020398B1 (ru) 2014-10-30
NZ592215A (en) 2012-09-28
TWI477284B (zh) 2015-03-21
JO3097B1 (ar) 2017-03-15
JP2012509881A (ja) 2012-04-26
DK2358755T3 (en) 2015-11-16
TW201023885A (en) 2010-07-01
CA2743508A1 (en) 2010-05-27
ES2549760T3 (es) 2015-11-02
PT2358755E (pt) 2015-11-12
CN102216333A (zh) 2011-10-12
BRPI0922800A2 (pt) 2015-12-22
WO2010059654A1 (en) 2010-05-27
US8217148B2 (en) 2012-07-10
CY1116886T1 (el) 2017-04-05
CA2743508C (en) 2016-07-19
KR101334450B1 (ko) 2013-12-02
EP2358755A1 (en) 2011-08-24
HRP20151019T1 (hr) 2015-10-23
US20120263723A1 (en) 2012-10-18
US20100129369A1 (en) 2010-05-27
EP2963058B1 (en) 2018-02-21
HK1158229A1 (en) 2012-07-13
CN102216333B (zh) 2014-05-21
AU2009316742A1 (en) 2010-05-27
ES2663825T3 (es) 2018-04-17
PL2358755T3 (pl) 2016-01-29
IL212633A0 (en) 2011-07-31
KR20110074612A (ko) 2011-06-30
EP2358755B1 (en) 2015-09-02

Similar Documents

Publication Publication Date Title
PA8849001A1 (es) Anticuerpos de c-met
ECSP12011694A (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2-humana
BR112015023797A2 (pt) proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
GT201200318A (es) Anticuerpos hacia gdf8 humano
EA201490546A1 (ru) Замещенные аннелированные пиримидины и их применение
EA201591754A1 (ru) Человеческие антитела к na1.7
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
MX2011010707A (es) Anticuerpos dkk-1.
MX379297B (es) Compuestos alqueno tetrasustituidos y su uso.
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
MX2016001236A (es) Anticuerpos anti-fgfr2iiib afucosilados.
AR083044A1 (es) Anticuerpos anti-cd48 y usos de los mismos
AR092662A1 (es) Anticuerpos anti-ddr1
MX2013012088A (es) Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.
CR20130621A (es) Anticuerpos anti-angptl3 y usos de los mismos
ECSP13012712A (es) Mutantes fc de anticuerpos resistentes a proteasas activas
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
CL2012001141A1 (es) Anticuerpo aislado o fragmento de este que se une específicamente a interleuquina-17a (il-17a) humana.
EA201590402A1 (ru) ЧЕЛОВЕЧЕСКИЕ АНТИТЕЛА ПРОТИВ GFRα3 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
BR112014015851A2 (pt) proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
CO2018001840A2 (es) Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5
AR115288A1 (es) Anticuerpos humanizados contra el psma
UY39436A (es) Proteínas de unión específicas y sus usos